Bharat Biotech, a global leader in vaccine development and innovation, announced today that the safety and efficacy analysis data from Phase III clinical trials of COVAXIN® is peer reviewed and published in The Lancet.
from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/3kwNYhL
Home »
Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com
» Bharat Biotech’s COVAXIN® Phase III data published in The Lancet
https://ift.tt/eA8V8J
No comments:
Post a Comment